Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium.

Robert Koivula, Alison Heggie, Anna Barnett, Henna Cederberg, Tue H Hansen, Anitra D Koopman, Martin Ridderstråle, Femke Rutters, Henrik Vestergaard, Ramneek Gupta, Sanna Herrgård, Martijn W Heymans, Mandy H Perry, Simone Rauh, Maritta Siloaho, Harriet J A Teare, Barbara Thorand, Jimmy Bell, Søren Brunak, Gary FrostBernd Jablonka, Andrea Mari, Tim J McDonald, Jacqueline M Dekker, Torben Hansen, Andrew Hattersley, Markku Laakso, Oluf Pedersen, Veikko Koivisto, Hartmut Ruetten, Mark Walker, Ewan Pearson, Paul Franks

Research output: Contribution to journalArticlepeer-review

36 Citations (SciVal)
152 Downloads (Pure)

Abstract

The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT.
Original languageEnglish
Pages (from-to)1132-1142
JournalDiabetologia
Volume57
Issue number6
DOIs
Publication statusPublished - 2014

Subject classification (UKÄ)

  • Endocrinology and Diabetes

Fingerprint

Dive into the research topics of 'Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium.'. Together they form a unique fingerprint.

Cite this